Form 4: Artivion SVP Marshall S. Stanton Reports Stock Sales
SEC Form 4 Filing
Marshall S. Stanton, SVP of Clinical & MD Affairs at Artivion, Inc., reported the sale of common stock on May 9, 2025.
Summary
- On May 9, 2025, Marshall S. Stanton, SVP of Clinical & MD Affairs at Artivion, Inc., sold shares of Artivion's common stock.
- He sold 5,737 shares at a weighted average price of $29.1302, with prices ranging from $28.97 to $29.25.
- He also sold 4,811 shares at a weighted average price of $29.1302, with prices ranging from $28.97 to $29.25.
- Following these transactions, Stanton directly owns 105,332 shares of Artivion common stock.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock sales by an executive. It doesn't inherently indicate positive or negative performance for the company.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency into the trading activities of key personnel.
Stakeholder Impact
- The stock sale by a company insider could be perceived neutrally or slightly negatively by shareholders, depending on the context and reasons for the sale.
Key Dates
| Date | Description |
|---|---|
| 05/09/2025 | Date of stock sale transactions |
| 05/12/2025 | Date of signature on the Form 4 filing |
Keywords
Form 4, Artivion, AORT, Stock Sale, Insider Trading, Marshall S. Stanton, SVP Clinical & MD Affairs, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.